Fatty acid composition of lipid fractions in white- and brown-like adipocytes derived from human mesenchymal stem cells.
Abbasi K., Mehdizadeh A., Hamishehkar H., Nouri M., Darabi M.
Laboratory Study, published in Adipocyte (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Adipocyte (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41035192
- PMCID
- PMC12498536
- DOI
- 10.1080/21623945.2025.2566481
Abstract (original English)
White and brown adipocytes differ markedly in lipid composition and metabolic function. White adipocytes primarily serve as energy storage depots, whereas brown adipocytes are mitochondria-rich and specialized for thermogenesis. However, the lipidomic profiles of white-like (WLAs) and brown-like adipocytes (BLAs) differentiated from human mesenchymal stem cells (MSCs) remain incompletely characterized. Human adipose-derived MSCs were differentiated into WLAs and BLAs. Lipid fractions were isolated and analysed by gas-liquid chromatography. Fatty acid composition data were used to calculate indices of stearoyl-CoA desaturase-1 (SCD1) activity, elongation, and ω6 synthesis. Compared to MSCs, BLAs showed consistently elevated oleate (≥4.2-fold) and stearate (≥2.3-fold), along with reduced palmitate (≤-20%) and linoleate (≤-28%) across phospholipid, triglyceride, and free fatty acid fractions. WLAs versus MSCs showed similar trends, with oleate increasing up to 15-fold and palmitate decreasing by 67-82% depending on the lipid class. SCD1 activity and elongation indices were elevated in WLAs (SCD1: up to 4.7-fold; elongation: up to 28-fold). The ω6 synthesis index was also increased in triglyceride and free fatty acid fractions of WLAs (≥3.3-fold), but markedly suppressed in BLAs (≤-88.7%). WLAs and BLAs differentiated from MSCs exhibit distinct lipid profiles and inferred enzymatic
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.